£1 billion Spire Healthcare explores sale as shareholders push for premium valuation

FTSE 250 private hospital operator appoints Rothschild to review strategic options, including potential sale, as investors argue current market cap fails to reflect £1.4bn property portfolio value

Spire Healthcare Group, the UK's largest independent healthcare provider, has confirmed it is exploring strategic alternatives including a potential sale, following sustained pressure from major shareholders who believe the company is significantly undervalued by the market.

The announcement on 18 September triggered an immediate 14% surge in Spire's share price to 247 pence, valuing the company at approximately £1 billion. The FTSE 250 company has appointed Rothschild & Co to conduct a comprehensive strategic review, marking the latest chapter in what has become a persistent valuation dispute between management and key investors.

The investment case: hidden asset value

Central to the shareholder pressure is Spire's substantial property portfolio, comprising 19 freehold hospital properties valued at over £1.4 billion. This asset base significantly exceeds the company's market capitalisation, creating what activists argue is a compelling value arbitrage opportunity.

Harwood Capital Management, holding approximately 5% of shares, has been particularly vocal in pushing for a sale process. "We believe Spire's current share price fails to reflect the company's value, most notably its unencumbered hospital portfolio worth in excess of £1.4 billion," the firm stated.

The property-heavy investment thesis is supported by Spire's operational profile. The company operates 38 hospitals and over 50 clinics across England, Wales and Scotland, serving more than one million patients annually through partnerships with 8,700 consultants. This infrastructure generates revenues of £1.51 billion, yet the market valuation suggests investors are pricing in significant operational challenges or asset impairments.

Market dynamics favour healthcare assets

For potential acquirers, Spire's positioning appears increasingly attractive given current UK healthcare market dynamics. NHS waiting lists have reached 7.4 million people, driving a 7% increase in private admissions as patients seek alternatives to prolonged public sector delays.

This demand surge has translated into a diversified revenue mix for Spire: 44% from private medical insurance, 30% from NHS contracts, 23% from self-pay patients, and 4% from corporate sources. The NHS contract component provides stable, government-backed revenues while private demand continues expanding.

Recent government agreements have further strengthened this dynamic. In January 2025, the NHS struck deals with independent providers to expand capacity, with the sector estimating it could provide an additional one million appointments annually. For acquirers seeking recession-resistant healthcare assets with inflation-linked pricing, this represents an increasingly compelling proposition.

Previous takeover attempts signal ongoing interest

Spire's strategic review follows multiple unsuccessful takeover attempts that demonstrate sustained acquirer interest while highlighting valuation disagreements.

Most notably, Australian healthcare group Ramsay Health Care pursued an extended campaign in 2021, ultimately offering 250 pence per share in what it described as its "final offer". Despite board recommendation, the bid failed to achieve required 75% shareholder approval, receiving only 69.9% support.

Opposition came primarily from institutional shareholders including Toscafund Asset Management (17.9% stake) and Fidelity International, who argued the offer undervalued the business given anticipated post-pandemic recovery in private healthcare demand. Their resistance proved prescient, with private healthcare volumes subsequently exceeding pre-pandemic levels.

Earlier, in 2017, Mediclinic International made a cash and share offer valuing each Spire share at 298.6 pence. The board unanimously rejected this proposal, stating it "significantly undervalues Spire and its prospects."

Strategic buyer opportunities

For strategic acquirers, Spire presents multiple value creation opportunities beyond the property arbitrage. The company's occupational health business has management ambitions to deliver £40 million annual EBITDA over the medium term, suggesting scope for operational expansion.

International healthcare operators, particularly from the US, may find UK expansion attractive as domestic Medicaid pressures affect home market operations. The UK's regulatory environment for private healthcare remains supportive, with government policy increasingly recognising the independent sector's role in addressing NHS capacity constraints.

Private equity interest has also been noted, with funds seeking defensive healthcare assets offering predictable cash flows and inflation protection. The substantial property portfolio provides both operational necessity and potential exit optionality through sale-and-leaseback arrangements.

Financial performance and management track record

Under CEO Justin Ash's leadership since 2017, Spire has implemented strategic and efficiency initiatives, though the board acknowledges these haven't been fully reflected in market valuation. The company expects to deliver additional cost savings of £20 million in the second half of 2025, building on £10 million achieved in the first half.

RBC Capital Markets maintains an "Outperform" rating with a 310 pence price target, representing potential 25% upside from current levels. Analyst consensus suggests average fair value of 294 pence, indicating broad professional recognition of the valuation disconnect.

What happens next

Spire emphasised the strategic review remains "highly preliminary" with no decisions made regarding specific options. The company stated it has not received approaches and isn't currently in discussions with potential bidders.

However, Rothschild's appointment signals serious evaluation of alternatives. Chairman Sir Ian Cheshire commented: "In July we made clear that the Board believed that Spire was undervalued by the market given its strategic progress and property underpin, and that we would continue to actively evaluate and implement any appropriate action that drives long-term shareholder value."

For business buyers monitoring UK healthcare opportunities, Spire's strategic review represents a significant test case for how persistent shareholder pressure combined with clear asset values can catalyse strategic alternatives, even among established public companies with previous takeover resistance.

The outcome will likely influence similar considerations across the UK healthcare sector, particularly as demand dynamics continue favouring private providers amid ongoing NHS capacity constraints.

Share this article

Latest Medical Businesses for Sale

View more businesses for sale